Erivedge(vismodegib)
Erivedge (vismodegib) is a small molecule pharmaceutical. Vismodegib was first approved as Erivedge on 2012-01-30. It is used to treat skin neoplasms in the USA. It has been approved in Europe to treat basal cell neoplasms. The pharmaceutical is active against protein smoothened.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Erivedge
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| erivedge | New Drug Application | 2023-03-27 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| skin neoplasms | EFO_0004198 | D012878 | C44 |
| basal cell neoplasms | — | D018295 | — |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
91 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 8 | 22 | — | 2 | 5 | 36 |
| Basal cell carcinoma | D002280 | — | — | 4 | 19 | — | 2 | 6 | 30 |
| Basal cell neoplasms | D018295 | — | — | 2 | 17 | — | 2 | 6 | 27 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 5 | 12 | — | — | 1 | 17 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 6 | 4 | — | — | — | 9 |
| Adenocarcinoma | D000230 | — | — | 4 | 5 | — | — | — | 8 |
| Recurrence | D012008 | — | — | 4 | 4 | — | — | — | 7 |
| Syndrome | D013577 | — | — | 1 | 5 | — | — | 1 | 7 |
| Basal cell nevus syndrome | D001478 | EFO_0004136 | — | 1 | 5 | — | — | 1 | 7 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 3 | — | — | — | 6 |
| Prostatic neoplasms | D011471 | — | C61 | 4 | 2 | — | — | — | 5 |
| Multiple myeloma | D009101 | — | C90.0 | 2 | 3 | — | — | — | 5 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | 3 | — | — | 1 | 5 |
Show 86 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
| Primary myelofibrosis | D055728 | — | D47.4 | 2 | — | — | — | — | 2 |
| Acinar cell carcinoma | D018267 | — | — | 2 | — | — | — | — | 2 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 1 | — | — | — | — | 1 |
| Myeloproliferative disorders | D009196 | — | D47.1 | 1 | — | — | — | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | — | 1 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | — | — | — | — | 1 |
| Anemia | D000740 | HP_0001903 | D64.9 | 1 | — | — | — | — | 1 |
| Hodgkin disease | D006689 | — | C81 | 1 | — | — | — | — | 1 |
Show 8 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Spasm | D013035 | — | M62.83 | — | — | — | — | 1 | 1 |
| Musculoskeletal pain | D059352 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Vismodegib |
| INN | vismodegib |
| Description | Vismodegib is a benzamide obtained by formal condensation between the carboxy group of 2-chloro-4-(methylsulfonyl)benzoic acid and the anilino group of 4-chloro-3-(pyridin-2-yl)aniline. Used for the treatment metastatic basal cell carcinoma. It has a role as an antineoplastic agent, a SMO receptor antagonist, a Hedgehog signaling pathway inhibitor and a teratogenic agent. It is a sulfone, a member of benzamides, a member of pyridines and a member of monochlorobenzenes. |
| Classification | Small molecule |
| Drug class | hedgehog signaling inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1 |
Identifiers
| PDB | — |
| CAS-ID | 879085-55-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL473417 |
| ChEBI ID | 66903 |
| PubChem CID | 24776445 |
| DrugBank | DB08828 |
| UNII ID | 25X868M3DS (ChemIDplus, GSRS) |
Target
Agency Approved
SMO
SMO
Organism
Homo sapiens
Gene name
SMO
Gene synonyms
SMOH
NCBI Gene ID
Protein name
protein smoothened
Protein synonyms
frizzled family member 11, Protein Gx, seven transmembrane helix receptor, smoothened homolog, smoothened, frizzled family receptor, smoothened, seven transmembrane spanning receptor
Uniprot ID
Mouse ortholog
Smo (319757)
protein smoothened (P56726)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Erivedge – Roche
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,003 documents
View more details
Safety
Black-box Warning
Black-box warning for: Erivedge
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
8,052 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use